Two developments reported on September 26, 2026, highlight the accelerating convergence of AI and wearable health technology. Insilico Medicine, in collaboration with Liquid AI, the Buck Institute for Research on Aging, Harvard Medical School, and Brigham and Women’s Hospital, published a suite of open-access AI tools in Cell: the LongevityBench benchmark, compact Longevity-LLMs, and the LongevityClaw agent platform — all designed to accelerate global aging research. This follows the company’s earlier breakthrough in Nature Biotechnology, where the AI-discovered drug candidate rentosertib reduced biological age by six years across six independent proteomic aging clocks in a Phase IIa trial. Separately, the women’s health platform Xella Health announced integration with Oura smart rings, allowing users to share sleep data, heart rate variability, resting heart rate, temperature trends, physical activity, and menstrual cycle information. Xella combines AI analysis and multi-omics testing with telemedicine consultations to create personalized treatment programs, and the Oura integration adds a continuous physiological data stream to the platform’s decision engine.
About the Author
